-
公开(公告)号：EP2118135A1
公开(公告)日：2009-11-18
申请号：EP07818640.0
申请日：2007-10-02
发明人： GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , BRÜGGEMEIER, Ulf , ALBRECHT-KÜPPER, Barbara , KLEIN, Martina
CPC分类号： G01N33/6887 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158
摘要： The invention provides CRTAC which is associated with the cardiovascular diseases, hematological diseases, respiratory diseases, cancer, gastrointestinal and liver disease, inflammation, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, respiratory diseases, cancer, gastrointestinal and liver disease, inflammation, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CRTAC as well as pharmaceutical compositions comprising such compounds. The invention also provides CRTAC as a biomarker for diseases as cardiovascular diseases, hematological diseases, respiratory diseases, cancer, gastrointestinal and liver disease, inflammation, neurological diseases and urological diseases.
-
公开(公告)号：EP2102357A1
公开(公告)日：2009-09-23
申请号：EP07818638.4
申请日：2007-10-02
发明人： GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , BRÜGGEMEIER, Ulf , ALBRECHT-KÜPPER, Barbara , KLEIN, Martina , STEPPAN, Sonja , ELLINGHAUS, Peter , D'URSO, Donatella , SEEWALD, Michael , MILTING, Hendrik
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , Y10S530/841
摘要： The invention provides LTBP2 which is associated with the cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases and urological diseases
-
公开(公告)号：EP1235595B8
公开(公告)日：2009-10-07
申请号：EP00965901.2
申请日：2000-08-28
发明人： LERCHEN, Hans-Georg , BAUMGARTEN, Jörg , BRÜGGEMEIER, Ulf , ALBERS, Markus , SCHOOP, Andreas , SCHULZE, Thomas-J
IPC分类号： A61K47/48
CPC分类号： A61K47/55
摘要： The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.
摘要翻译： 本发明涉及由于通过优选的连接单位与αvβ3整联蛋白拮抗剂连接而具有肿瘤特异性作用的细胞抑制剂。 优选的连接单元保证细胞生长抑制剂和αvβ3整联蛋白拮抗剂的缀合物的血清稳定性，同时由于其释放细胞生长抑制剂的酶促或水解可裂解性而在肿瘤细胞中具有所需的细胞内作用。
-
-
搜索结果
3 条记录 (耗时 0.016 秒)
